Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum
Aim To evaluate obstetric outcomes in embryo transfer (ET) during estrogen with progestin hormone replacement therapy (HRT) cycles using assisted reproductive technology (ART). Methods Of the 118 singleton pregnancies conceived with ART and delivered between January 2015 and December 2017, we review...
Gespeichert in:
| Veröffentlicht in: | The journal of obstetrics and gynaecology research 2019-12, Vol.45 (12), p.2394-2399 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2399 |
|---|---|
| container_issue | 12 |
| container_start_page | 2394 |
| container_title | The journal of obstetrics and gynaecology research |
| container_volume | 45 |
| creator | Sakai, Yuya Ono, Masanori Iizuka, Takashi Kagami, Kyosuke Masumoto, Sakiko Nakayama, Midori Nakade, Kyohei Shitano, Yasushi Yamazaki, Rena Fujiwara, Hiroshi |
| description | Aim
To evaluate obstetric outcomes in embryo transfer (ET) during estrogen with progestin hormone replacement therapy (HRT) cycles using assisted reproductive technology (ART).
Methods
Of the 118 singleton pregnancies conceived with ART and delivered between January 2015 and December 2017, we reviewed the data of 87 cases that had information on HRT at the time of ET. Data on pregnancy outcomes included the presence of small for gestational age fetuses, hypertensive disorders of pregnancy, placenta previa (including low‐lying placenta), placental abruption and placenta accreta spectrum (including placenta accreta, placenta increta and placenta percreta). We investigated the relationship between HRT cycles and adverse placental outcomes (placenta accreta spectrum, placental abruption, placenta previa, hypertensive disorders of pregnancy and small for gestational age fetuses). We then analyzed the associations that correlated with adverse placental outcomes.
Results
Patients with ET during HRT cycles were more likely to have placenta accreta spectrum. During the study period, 87 out of 118 singleton live births using ART had information on HRT (60 HRT cycles and 27 ovulation cycles). The incidence of placenta accreta spectrum was significantly higher in the HRT cycle group than in the ovulation cycle group (HRT cycle, 31.7% [19 of 60] vs ovulation cycle, 7.4% [2 of 27]; P |
| doi_str_mv | 10.1111/jog.14111 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2281849360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2281849360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3771-f09ae1ca414bf36b789d756d9c1c29b657774bfc5ace61df3e8bcb5e5677f153</originalsourceid><addsrcrecordid>eNp1kc9O3DAQxq2KqvxpD30BZIlLewhk4jhOjtWKQiskLtwjZzLZ9SqxF9spykPwzvWywKFSfZmR_fu-Getj7Cvkl5DO1datL6FM3Qd2AmWpslzJ6ij1ooSszlV1zE5D2OY5qAbqT-xYQCkrAXDCnq-nzi-OR69tGMhzHYJDoyP1_MnEDd84PzlL3NNu1EgT2cjjhrzeLRwXHCnwORi73gtN2MsS6V0_YzR_iEfCjXWjWy_cWPSkQxK8ONmoucZ0lWrYEUY_T5_Zx0GPgb681jP28PP6YXWb3d3f_Fr9uMtQKAXZkDeaAHUJZTeIqlN106cf9w0CFk1XSaVUekGZxlTQD4LqDjtJslJqACnO2LeDbVr0caYQ28kEpHHUltwc2qKooS4bUeUJvfgH3brZ27RcW4gCoBFSqkR9P1DoXQiehnbnzaT90kLe7iNKqnX7ElFiz18d526i_p18yyQBVwfgyYy0_N-p_X1_c7D8C3fcntA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2321193557</pqid></control><display><type>article</type><title>Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum</title><source>Wiley Journals</source><creator>Sakai, Yuya ; Ono, Masanori ; Iizuka, Takashi ; Kagami, Kyosuke ; Masumoto, Sakiko ; Nakayama, Midori ; Nakade, Kyohei ; Shitano, Yasushi ; Yamazaki, Rena ; Fujiwara, Hiroshi</creator><creatorcontrib>Sakai, Yuya ; Ono, Masanori ; Iizuka, Takashi ; Kagami, Kyosuke ; Masumoto, Sakiko ; Nakayama, Midori ; Nakade, Kyohei ; Shitano, Yasushi ; Yamazaki, Rena ; Fujiwara, Hiroshi</creatorcontrib><description>Aim
To evaluate obstetric outcomes in embryo transfer (ET) during estrogen with progestin hormone replacement therapy (HRT) cycles using assisted reproductive technology (ART).
Methods
Of the 118 singleton pregnancies conceived with ART and delivered between January 2015 and December 2017, we reviewed the data of 87 cases that had information on HRT at the time of ET. Data on pregnancy outcomes included the presence of small for gestational age fetuses, hypertensive disorders of pregnancy, placenta previa (including low‐lying placenta), placental abruption and placenta accreta spectrum (including placenta accreta, placenta increta and placenta percreta). We investigated the relationship between HRT cycles and adverse placental outcomes (placenta accreta spectrum, placental abruption, placenta previa, hypertensive disorders of pregnancy and small for gestational age fetuses). We then analyzed the associations that correlated with adverse placental outcomes.
Results
Patients with ET during HRT cycles were more likely to have placenta accreta spectrum. During the study period, 87 out of 118 singleton live births using ART had information on HRT (60 HRT cycles and 27 ovulation cycles). The incidence of placenta accreta spectrum was significantly higher in the HRT cycle group than in the ovulation cycle group (HRT cycle, 31.7% [19 of 60] vs ovulation cycle, 7.4% [2 of 27]; P < 0.01).
Conclusion
The obstetric outcomes occurring in pregnancies involving HRT use may differ among ET cycles. ET during HRT cycles were associated with adverse obstetric outcomes due to placenta accreta spectrum. The potential interaction between HRT cycles and adverse placental events is novel and warrants further investigation.</description><identifier>ISSN: 1341-8076</identifier><identifier>EISSN: 1447-0756</identifier><identifier>DOI: 10.1111/jog.14111</identifier><identifier>PMID: 31456311</identifier><language>eng</language><publisher>Kyoto, Japan: John Wiley & Sons Australia, Ltd</publisher><subject>assisted reproductive technology ; Embryo transfer ; Estrogens ; Fetuses ; Gestational age ; Hormone replacement therapy ; Hypertension ; morbidly adherent placenta ; Obstetrics ; Ovulation ; Placenta ; placenta accreta spectrum ; Pregnancy ; Pregnancy complications ; Progestin ; Reproductive technologies ; Reproductive technology ; Small-for-gestational age</subject><ispartof>The journal of obstetrics and gynaecology research, 2019-12, Vol.45 (12), p.2394-2399</ispartof><rights>2019 Japan Society of Obstetrics and Gynecology</rights><rights>2019 Japan Society of Obstetrics and Gynecology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3771-f09ae1ca414bf36b789d756d9c1c29b657774bfc5ace61df3e8bcb5e5677f153</citedby><cites>FETCH-LOGICAL-c3771-f09ae1ca414bf36b789d756d9c1c29b657774bfc5ace61df3e8bcb5e5677f153</cites><orcidid>0000-0001-9249-6813</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjog.14111$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjog.14111$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31456311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sakai, Yuya</creatorcontrib><creatorcontrib>Ono, Masanori</creatorcontrib><creatorcontrib>Iizuka, Takashi</creatorcontrib><creatorcontrib>Kagami, Kyosuke</creatorcontrib><creatorcontrib>Masumoto, Sakiko</creatorcontrib><creatorcontrib>Nakayama, Midori</creatorcontrib><creatorcontrib>Nakade, Kyohei</creatorcontrib><creatorcontrib>Shitano, Yasushi</creatorcontrib><creatorcontrib>Yamazaki, Rena</creatorcontrib><creatorcontrib>Fujiwara, Hiroshi</creatorcontrib><title>Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum</title><title>The journal of obstetrics and gynaecology research</title><addtitle>J Obstet Gynaecol Res</addtitle><description>Aim
To evaluate obstetric outcomes in embryo transfer (ET) during estrogen with progestin hormone replacement therapy (HRT) cycles using assisted reproductive technology (ART).
Methods
Of the 118 singleton pregnancies conceived with ART and delivered between January 2015 and December 2017, we reviewed the data of 87 cases that had information on HRT at the time of ET. Data on pregnancy outcomes included the presence of small for gestational age fetuses, hypertensive disorders of pregnancy, placenta previa (including low‐lying placenta), placental abruption and placenta accreta spectrum (including placenta accreta, placenta increta and placenta percreta). We investigated the relationship between HRT cycles and adverse placental outcomes (placenta accreta spectrum, placental abruption, placenta previa, hypertensive disorders of pregnancy and small for gestational age fetuses). We then analyzed the associations that correlated with adverse placental outcomes.
Results
Patients with ET during HRT cycles were more likely to have placenta accreta spectrum. During the study period, 87 out of 118 singleton live births using ART had information on HRT (60 HRT cycles and 27 ovulation cycles). The incidence of placenta accreta spectrum was significantly higher in the HRT cycle group than in the ovulation cycle group (HRT cycle, 31.7% [19 of 60] vs ovulation cycle, 7.4% [2 of 27]; P < 0.01).
Conclusion
The obstetric outcomes occurring in pregnancies involving HRT use may differ among ET cycles. ET during HRT cycles were associated with adverse obstetric outcomes due to placenta accreta spectrum. The potential interaction between HRT cycles and adverse placental events is novel and warrants further investigation.</description><subject>assisted reproductive technology</subject><subject>Embryo transfer</subject><subject>Estrogens</subject><subject>Fetuses</subject><subject>Gestational age</subject><subject>Hormone replacement therapy</subject><subject>Hypertension</subject><subject>morbidly adherent placenta</subject><subject>Obstetrics</subject><subject>Ovulation</subject><subject>Placenta</subject><subject>placenta accreta spectrum</subject><subject>Pregnancy</subject><subject>Pregnancy complications</subject><subject>Progestin</subject><subject>Reproductive technologies</subject><subject>Reproductive technology</subject><subject>Small-for-gestational age</subject><issn>1341-8076</issn><issn>1447-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kc9O3DAQxq2KqvxpD30BZIlLewhk4jhOjtWKQiskLtwjZzLZ9SqxF9spykPwzvWywKFSfZmR_fu-Getj7Cvkl5DO1datL6FM3Qd2AmWpslzJ6ij1ooSszlV1zE5D2OY5qAbqT-xYQCkrAXDCnq-nzi-OR69tGMhzHYJDoyP1_MnEDd84PzlL3NNu1EgT2cjjhrzeLRwXHCnwORi73gtN2MsS6V0_YzR_iEfCjXWjWy_cWPSkQxK8ONmoucZ0lWrYEUY_T5_Zx0GPgb681jP28PP6YXWb3d3f_Fr9uMtQKAXZkDeaAHUJZTeIqlN106cf9w0CFk1XSaVUekGZxlTQD4LqDjtJslJqACnO2LeDbVr0caYQ28kEpHHUltwc2qKooS4bUeUJvfgH3brZ27RcW4gCoBFSqkR9P1DoXQiehnbnzaT90kLe7iNKqnX7ElFiz18d526i_p18yyQBVwfgyYy0_N-p_X1_c7D8C3fcntA</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Sakai, Yuya</creator><creator>Ono, Masanori</creator><creator>Iizuka, Takashi</creator><creator>Kagami, Kyosuke</creator><creator>Masumoto, Sakiko</creator><creator>Nakayama, Midori</creator><creator>Nakade, Kyohei</creator><creator>Shitano, Yasushi</creator><creator>Yamazaki, Rena</creator><creator>Fujiwara, Hiroshi</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9249-6813</orcidid></search><sort><creationdate>201912</creationdate><title>Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum</title><author>Sakai, Yuya ; Ono, Masanori ; Iizuka, Takashi ; Kagami, Kyosuke ; Masumoto, Sakiko ; Nakayama, Midori ; Nakade, Kyohei ; Shitano, Yasushi ; Yamazaki, Rena ; Fujiwara, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3771-f09ae1ca414bf36b789d756d9c1c29b657774bfc5ace61df3e8bcb5e5677f153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>assisted reproductive technology</topic><topic>Embryo transfer</topic><topic>Estrogens</topic><topic>Fetuses</topic><topic>Gestational age</topic><topic>Hormone replacement therapy</topic><topic>Hypertension</topic><topic>morbidly adherent placenta</topic><topic>Obstetrics</topic><topic>Ovulation</topic><topic>Placenta</topic><topic>placenta accreta spectrum</topic><topic>Pregnancy</topic><topic>Pregnancy complications</topic><topic>Progestin</topic><topic>Reproductive technologies</topic><topic>Reproductive technology</topic><topic>Small-for-gestational age</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sakai, Yuya</creatorcontrib><creatorcontrib>Ono, Masanori</creatorcontrib><creatorcontrib>Iizuka, Takashi</creatorcontrib><creatorcontrib>Kagami, Kyosuke</creatorcontrib><creatorcontrib>Masumoto, Sakiko</creatorcontrib><creatorcontrib>Nakayama, Midori</creatorcontrib><creatorcontrib>Nakade, Kyohei</creatorcontrib><creatorcontrib>Shitano, Yasushi</creatorcontrib><creatorcontrib>Yamazaki, Rena</creatorcontrib><creatorcontrib>Fujiwara, Hiroshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of obstetrics and gynaecology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sakai, Yuya</au><au>Ono, Masanori</au><au>Iizuka, Takashi</au><au>Kagami, Kyosuke</au><au>Masumoto, Sakiko</au><au>Nakayama, Midori</au><au>Nakade, Kyohei</au><au>Shitano, Yasushi</au><au>Yamazaki, Rena</au><au>Fujiwara, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum</atitle><jtitle>The journal of obstetrics and gynaecology research</jtitle><addtitle>J Obstet Gynaecol Res</addtitle><date>2019-12</date><risdate>2019</risdate><volume>45</volume><issue>12</issue><spage>2394</spage><epage>2399</epage><pages>2394-2399</pages><issn>1341-8076</issn><eissn>1447-0756</eissn><abstract>Aim
To evaluate obstetric outcomes in embryo transfer (ET) during estrogen with progestin hormone replacement therapy (HRT) cycles using assisted reproductive technology (ART).
Methods
Of the 118 singleton pregnancies conceived with ART and delivered between January 2015 and December 2017, we reviewed the data of 87 cases that had information on HRT at the time of ET. Data on pregnancy outcomes included the presence of small for gestational age fetuses, hypertensive disorders of pregnancy, placenta previa (including low‐lying placenta), placental abruption and placenta accreta spectrum (including placenta accreta, placenta increta and placenta percreta). We investigated the relationship between HRT cycles and adverse placental outcomes (placenta accreta spectrum, placental abruption, placenta previa, hypertensive disorders of pregnancy and small for gestational age fetuses). We then analyzed the associations that correlated with adverse placental outcomes.
Results
Patients with ET during HRT cycles were more likely to have placenta accreta spectrum. During the study period, 87 out of 118 singleton live births using ART had information on HRT (60 HRT cycles and 27 ovulation cycles). The incidence of placenta accreta spectrum was significantly higher in the HRT cycle group than in the ovulation cycle group (HRT cycle, 31.7% [19 of 60] vs ovulation cycle, 7.4% [2 of 27]; P < 0.01).
Conclusion
The obstetric outcomes occurring in pregnancies involving HRT use may differ among ET cycles. ET during HRT cycles were associated with adverse obstetric outcomes due to placenta accreta spectrum. The potential interaction between HRT cycles and adverse placental events is novel and warrants further investigation.</abstract><cop>Kyoto, Japan</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>31456311</pmid><doi>10.1111/jog.14111</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9249-6813</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-8076 |
| ispartof | The journal of obstetrics and gynaecology research, 2019-12, Vol.45 (12), p.2394-2399 |
| issn | 1341-8076 1447-0756 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2281849360 |
| source | Wiley Journals |
| subjects | assisted reproductive technology Embryo transfer Estrogens Fetuses Gestational age Hormone replacement therapy Hypertension morbidly adherent placenta Obstetrics Ovulation Placenta placenta accreta spectrum Pregnancy Pregnancy complications Progestin Reproductive technologies Reproductive technology Small-for-gestational age |
| title | Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A43%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Embryo%20transfer%20associated%20with%20hormone%20replacement%20therapy%20cycles%20using%20assisted%20reproductive%20technology%20increases%20placenta%20accreta%20spectrum&rft.jtitle=The%20journal%20of%20obstetrics%20and%20gynaecology%20research&rft.au=Sakai,%20Yuya&rft.date=2019-12&rft.volume=45&rft.issue=12&rft.spage=2394&rft.epage=2399&rft.pages=2394-2399&rft.issn=1341-8076&rft.eissn=1447-0756&rft_id=info:doi/10.1111/jog.14111&rft_dat=%3Cproquest_cross%3E2281849360%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2321193557&rft_id=info:pmid/31456311&rfr_iscdi=true |